Last reviewed · How we verify
Forxiga
Forxiga is a Small molecule drug developed by AstraZeneca Turkey. It is currently FDA-approved for Chronic heart failure, Chronic kidney disease, Diabetes mellitus type 1. Also known as: Dapagliflozin, dapagliflozin, Dapagliflozin 10 mg.
At a glance
| Generic name | Forxiga |
|---|---|
| Also known as | Dapagliflozin, dapagliflozin, Dapagliflozin 10 mg |
| Sponsor | AstraZeneca Turkey |
| Target | Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Chronic heart failure
- Chronic kidney disease
- Diabetes mellitus type 1
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- SGLT2 Inhibition in Hemodialysis (PHASE2)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs (NA)
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction (PHASE3)
- iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (PHASE3)
- Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) (PHASE3)
- Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Forxiga CI brief — competitive landscape report
- Forxiga updates RSS · CI watch RSS
- AstraZeneca Turkey portfolio CI
Frequently asked questions about Forxiga
What is Forxiga?
Forxiga is a Small molecule drug developed by AstraZeneca Turkey, indicated for Chronic heart failure, Chronic kidney disease, Diabetes mellitus type 1.
What is Forxiga used for?
Forxiga is indicated for Chronic heart failure, Chronic kidney disease, Diabetes mellitus type 1, Diabetes mellitus type 2.
Who makes Forxiga?
Forxiga is developed and marketed by AstraZeneca Turkey (see full AstraZeneca Turkey pipeline at /company/astrazeneca-turkey).
Is Forxiga also known as anything else?
Forxiga is also known as Dapagliflozin, dapagliflozin, Dapagliflozin 10 mg.
What development phase is Forxiga in?
Forxiga is FDA-approved (marketed).
What does Forxiga target?
Forxiga targets Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1.
Related
- Target: All drugs targeting Low affinity sodium-glucose cotransporter, Sodium/myo-inositol cotransporter 2, Sodium/glucose cotransporter 1
- Manufacturer: AstraZeneca Turkey — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Chronic heart failure
- Indication: Drugs for Chronic kidney disease
- Indication: Drugs for Diabetes mellitus type 1
- Also known as: Dapagliflozin, dapagliflozin, Dapagliflozin 10 mg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing